Edgewise Therapeutics (Edgewise Therapeutics) EPS (Diluted) : $-1.55 (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Edgewise Therapeutics EPS (Diluted)?

Edgewise Therapeutics's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.33. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.55.

Edgewise Therapeutics's EPS (Basic) for the three months ended in Mar. 2024 was $-0.33. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.55.

Edgewise Therapeutics's EPS without NRI for the three months ended in Mar. 2024 was $-0.33. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.55.

During the past 3 years, the average EPS without NRIGrowth Rate was -62.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 5 years, Edgewise Therapeutics's highest 3-Year average EPS without NRI Growth Rate was -38.20% per year. The lowest was -62.20% per year. And the median was -50.20% per year.

Edgewise Therapeutics EPS (Diluted) Historical Data

The historical data trend for Edgewise Therapeutics's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Edgewise Therapeutics EPS (Diluted) Chart

Edgewise Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Diluted)

-0.48

-0.37

-1.14

-1.26

-1.57

Edgewise Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EPS (Diluted)	Get a 7-Day Free Trial													-0.36	-0.34	-0.41	-0.47	-0.33

Competitive Comparison of Edgewise Therapeutics's EPS (Diluted)

For the Biotechnology subindustry, Edgewise Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Edgewise Therapeutics's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Edgewise Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Edgewise Therapeutics's PE Ratio falls into.

Edgewise Therapeutics EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Edgewise Therapeutics's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-100.163	-	0)	/	63.724
	=	-1.57

Edgewise Therapeutics's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-28.525	-	0)	/	87.567
	=	-0.33

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.55

Edgewise Therapeutics (NAS:EWTX) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Edgewise Therapeutics EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Edgewise Therapeutics's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Edgewise Therapeutics (Edgewise Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Edgewise Therapeutics Inc (NAS:EWTX) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

3415 Colorado Avenue, Boulder, CO, USA, 80303

Website

https://www.edgewisetx.com

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.

Executives

John R Moore	officer: General Counsel	3200 WALNUT ST, BOULDER CO 80301
Alan J Russell	director, officer: Chief Scientific Officer	3415 COLORADO AVE, BOULDER CO 80303
Jonathan C Fox	director	C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
R Michael Carruthers	officer: Chief Financial Officer	3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301
Behrad Derakhshan	officer: Chief Business Officer	3415 COLORADO AVE., BOULDER CO 80303
Kevin Koch	director, officer: President and CEO	3200 WALNUT ST, BOULDER CO 80301
Joanne M. Donovan	officer: CMO	C/O CATABASIS PHARMACEUTICALS, INC., ONE KENDALL SQ. BLDG. 1400E SUITE B14202, CAMBRIDGE MA 02139
Marc Semigran	officer: Chief Development Officer	C/O MYOKARDIA, INC., 333 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Peter A. Thompson	director, 10 percent owner	C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Orbimed Capital Gp Vi Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Jonathan D Root	director	2735 SAND HILL ROAD, MENLO PARK CA 94025
James E Flynn	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017